Advancing Vaccine Adjuvant Innovation
SPI Pharma is expanding its leadership in vaccine adjuvants through innovation, strategic investment, and partnerships. With over 20 years of alum expertise, we now offer saponin-based and advanced adjuvant systems, available for licensing at commercial scale to accelerate next-generation vaccine development worldwide.
SPI Pharma partners with Q-Vant Biosciences and Inimmune to strengthen our leadership in vaccine adjuvant solutions. With Q-Vant’s sustainable saponin extraction technology and Inimmune’s expertise in novel small molecule adjuvants and advanced adjuvants systems, we combine innovation, quality, and global reach to provide scalable, high-purity, and next-generation adjuvant solutions for the pharmaceutical industry.
Adjuvant Systems
SPI Pharma produces and supplies high-quality aluminum hydroxide adjuvants for human and animal health manufacturers—the most widely used and studied chemistry in the field of vaccine adjuvants worldwide. Through our partnership with Inimmune, we also enable commercial-scale access to cutting-edge, next-generation adjuvant technologies available for licensing to accelerate vaccine innovation globally.
Single Components
SPI Pharma’s immunostimulators portfolio includes saponin-based adjuvants and synthetic MPL analogue from our partners QVANT and Inimmune. These advanced molecules activate targeted immune pathways, enhancing vaccine efficacy and durability while offering scalable, GMP-ready solutions for next-generation human and animal vaccine development.